Abstract
Fondaparinux is a synthetic, five-saccharide chain, AT-dependent, anti-FXa agent. Studies showed that fondaparinux acts in prevention and treatment of venous thromboembolism and in ischemic heart disease, without significant bleeding risk. The drug inhibits thrombin generation, has long half-life and can be administered once-daily without laboratory monitoring. It may be used in HIT treatment.
Keywords: Antithrombotic, factor Xa inhibitor, heparin, low molecular weight heparin, fondaparinux
Mini-Reviews in Medicinal Chemistry
Title: Fondaparinux: Pharmacology and Clinical Experience in Cardiovascular Medicine
Volume: 7 Issue: 4
Author(s): V. Toschi and M. Lettino
Affiliation:
Keywords: Antithrombotic, factor Xa inhibitor, heparin, low molecular weight heparin, fondaparinux
Abstract: Fondaparinux is a synthetic, five-saccharide chain, AT-dependent, anti-FXa agent. Studies showed that fondaparinux acts in prevention and treatment of venous thromboembolism and in ischemic heart disease, without significant bleeding risk. The drug inhibits thrombin generation, has long half-life and can be administered once-daily without laboratory monitoring. It may be used in HIT treatment.
Export Options
About this article
Cite this article as:
Toschi V. and Lettino M., Fondaparinux: Pharmacology and Clinical Experience in Cardiovascular Medicine, Mini-Reviews in Medicinal Chemistry 2007; 7 (4) . https://dx.doi.org/10.2174/138955707780363819
DOI https://dx.doi.org/10.2174/138955707780363819 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clopidogrel, Aspirin and Proton Pump Inhibition after Percutaneous Valve Implants: An Update
Current Pharmaceutical Design A Study of Metabolic Parameters in Patients with Gout: A Single Center Study from Nepal
Endocrine, Metabolic & Immune Disorders - Drug Targets Probiotics and Oral Health
Current Pharmaceutical Design Endothelial Progenitor Cells and In-stent Restenosis
Current Stem Cell Research & Therapy Emerging Therapeutic Targets for Metabolic Syndrome: Lessons from Animal Models
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advancements in Pharmacological Stent Therapy Using Polymeric Materials: Opportunities and Challenges
Current Drug Delivery How Should Serum Uric Acid Concentrations be Interpreted in Patients with Hypertension?
Current Hypertension Reviews Matrix Metalloproteinases and their Tissue Inhibitors in Diabetes, Atherosclerosis and Prediction of the Cardiovascular Risk
Current Enzyme Inhibition Induction of Quinone Reductase NQO1 by Resveratrol in Human K562 Cells Involves the Antioxidant Response Element ARE and is Accompanied by Nuclear Translocation of Transcription Factor Nrf2
Medicinal Chemistry Human Cognitive and Neuro-Psychiatric Bio-Markers in the Cardiac Peri-Operative Patient
Current Molecular Medicine Impact of Metabolic Surgery on Type 2 Diabetes Mellitus, Cardiovascular Risk Factors, and Mortality: A Review
Current Hypertension Reviews Vasoactive Compounds in the Neonatal Period
Current Medicinal Chemistry Pathophysiological Role and Clinical Significance of Lipoprotein-Associated Phospholipase A<sub>2</sub> (Lp-PLA<sub>2</sub>) Bound to LDL and HDL
Current Pharmaceutical Design Nuclear Receptors as Potential Targets for Modulating Reverse Cholesterol Transport
Current Topics in Medicinal Chemistry Does Non-Alcoholic Fatty Liver Disease (NAFLD) Increase Cardiovascular Risk?
Endocrine, Metabolic & Immune Disorders - Drug Targets Non-cholesterol Sterols in the Diagnosis and Treatment of Dyslipidemias: A Review
Current Medicinal Chemistry The Polyamine Pathway as a Potential Target for Vascular Diseases: Focus on Restenosis
Current Vascular Pharmacology Editorial [Hot Topic: Heart Transplantation in Congenital Heart Disease (Guest Editor: Francesco Parisi)]
Current Cardiology Reviews The Role of Renin Angiotensin System Blockade in the Treatment of Atrial Fibrillation
Current Drug Targets - Cardiovascular & Hematological Disorders A Comparison of Emotional Decoding Abilities in Patients with Amnestic Mild Cognitive Impairment, Very Mild and Mild Alzheimer’s Disease
Current Alzheimer Research